TY - JOUR
T1 - Long non-coding RNAs
T2 - An emerging powerhouse in the battle between life and death of tumor cells
AU - Xiong, Xing Dong
AU - Ren, Xingcong
AU - Cai, Meng Yun
AU - Yang, Jay W.
AU - Liu, Xinguang
AU - Yang, Jin Ming
N1 - Funding Information:
The study was supported by grants from the National Natural Science Foundation of China ( 81370456 ), the National Scholarship Fund of China ( 201408440139 ), the Natural Science Foundation of Guangdong Province ( 2014A030311015 ) and the Foundation for Distinguished Talents in Higher Education of Guangdong ( GK1318 ).
Publisher Copyright:
© 2016 Elsevier Ltd. All rights reserved.
PY - 2016/5
Y1 - 2016/5
N2 - Long non-coding RNAs (lncRNAs) represent a class of non-protein coding transcripts longer than 200 nucleotides that have aptitude for regulating gene expression at the transcriptional, post-transcriptional or epigenetic levels. In recent years, lncRNAs, which are believed to be the largest transcript class in the transcriptomes, have emerged as important players in a variety of biological processes. Notably, the identification and characterization of numerous lncRNAs in the past decade has revealed a role for these molecules in the regulation of cancer cell survival and death. It is likely that this class of non-coding RNA constitutes a critical contributor to the assorted known or/and unknown mechanisms of intrinsic or acquired drug resistance. Moreover, the expression of lncRNAs is altered in various patho-physiological conditions, including cancer. Therefore, lncRNAs represent potentially important targets in predicting or altering the sensitivity or resistance of cancer cells to various therapies. Here, we provide an overview on the molecular functions of lncRNAs, and discuss their impact and importance in cancer development, progression, and therapeutic outcome. We also provide a perspective on how lncRNAs may alter the efficacy of cancer therapy and the promise of lncRNAs as novel therapeutic targets for overcoming chemoresistance. A better understanding of the functional roles of lncRNA in cancer can ultimately translate to the development of novel, lncRNA-based intervention strategies for the treatment or prevention of drug-resistant cancer.
AB - Long non-coding RNAs (lncRNAs) represent a class of non-protein coding transcripts longer than 200 nucleotides that have aptitude for regulating gene expression at the transcriptional, post-transcriptional or epigenetic levels. In recent years, lncRNAs, which are believed to be the largest transcript class in the transcriptomes, have emerged as important players in a variety of biological processes. Notably, the identification and characterization of numerous lncRNAs in the past decade has revealed a role for these molecules in the regulation of cancer cell survival and death. It is likely that this class of non-coding RNA constitutes a critical contributor to the assorted known or/and unknown mechanisms of intrinsic or acquired drug resistance. Moreover, the expression of lncRNAs is altered in various patho-physiological conditions, including cancer. Therefore, lncRNAs represent potentially important targets in predicting or altering the sensitivity or resistance of cancer cells to various therapies. Here, we provide an overview on the molecular functions of lncRNAs, and discuss their impact and importance in cancer development, progression, and therapeutic outcome. We also provide a perspective on how lncRNAs may alter the efficacy of cancer therapy and the promise of lncRNAs as novel therapeutic targets for overcoming chemoresistance. A better understanding of the functional roles of lncRNA in cancer can ultimately translate to the development of novel, lncRNA-based intervention strategies for the treatment or prevention of drug-resistant cancer.
UR - http://www.scopus.com/inward/record.url?scp=84964974521&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964974521&partnerID=8YFLogxK
U2 - 10.1016/j.drup.2016.04.001
DO - 10.1016/j.drup.2016.04.001
M3 - Review article
C2 - 27180308
AN - SCOPUS:84964974521
SN - 1368-7646
VL - 26
SP - 28
EP - 42
JO - Drug Resistance Updates
JF - Drug Resistance Updates
ER -